Presentation is loading. Please wait.

Presentation is loading. Please wait.

Experience with Erlotinib in Lung Adenocarcinoma Harboring a Coexisting KIF5B-RET Fusion Gene and EGFR Mutation: Report of a Rare Case  Fumihiko Hirai,

Published byHollie Terry Modified over 5 years ago

Similar presentations

Presentation on theme: "Experience with Erlotinib in Lung Adenocarcinoma Harboring a Coexisting KIF5B-RET Fusion Gene and EGFR Mutation: Report of a Rare Case  Fumihiko Hirai,"— Presentation transcript:

1 Experience with Erlotinib in Lung Adenocarcinoma Harboring a Coexisting KIF5B-RET Fusion Gene and EGFR Mutation: Report of a Rare Case  Fumihiko Hirai, MD, Mitsuhiro Takenoyama, MD, Kenichi Taguchi, MD, Ryo Toyozawa, MD, Eiko Inamasu, MD, Gouji Toyokawa, MD, Tsukihisa Yoshida, MD, Yoshimasa Shiraishi, MD, Tomoyoshi Takenaka, MD, Masafumi Yamaguchi, MD, Chie Ushijima, MD, Takashi Seto, MD, Sadanori Takeo, MD, Yukito Ichinose, MD  Journal of Thoracic Oncology  Volume 9, Issue 5, Pages e37-e39 (May 2014) DOI: /JTO Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Histology of (A) the primary tumor and (B) metastatic supraclavicular LN. (1) The adenocarcinoma component with a predominant papillary structure (hematoxylin and eosin, ×200). An immunohistochemical examination revealed that the primary lesion and metastatic lesion were both positive for (2) thyroid transcription factor 1 (TTF1)/Napsin A and (3) CK7 and negative for (4) monoclonal anti-anaplastic lymphoma kinase (ALK) antibodies (5A4, ×200). LN, lymph node. Journal of Thoracic Oncology 2014 9, e37-e39DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Results of fusion-specific reverse transcription polymerase chain reaction of the primary lesion and metastatic lymph node. KIF5B-RET fusion gene, predicted product size of 154 bp; (lane 1) no template control, (lane 2) primary lesion, (lane 3) metastatic LN, (lane 4) negative control, and (lane 5) positive control. Primers for detection of KIF5B (exon 15)-RET (exon 12) fusion genes: forward (KIF5B exon 15) 5′-CTTAAGGAAATGACCAACCACC-3′; and reverse (RET exon 12) 5′-TCCAAATTCGCCTTCTCCTAGAG-3′. Journal of Thoracic Oncology 2014 9, e37-e39DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Gene sequence analysis of (A) the primary tumor and (B) metastatic supraclavicular lymph node. A direct sequence analysis revealed a variant 1 mutation of the KIF5B-RET fusion gene in the metastatic lesion. Journal of Thoracic Oncology 2014 9, e37-e39DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Experience with Erlotinib in Lung Adenocarcinoma Harboring a Coexisting KIF5B-RET Fusion Gene and EGFR Mutation: Report of a Rare Case  Fumihiko Hirai,"

Similar presentations

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.
Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.
Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.

Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 
Dramatic Response to Crizotinib in an ALK-Positive Adenocarcinoma Patient with Disseminated Intravascular Coagulation  Gouji Toyokawa, MD, PhD, Mitsuhiro.

Dramatic Response to Crizotinib in an ALK-Positive Adenocarcinoma Patient with Disseminated Intravascular Coagulation  Gouji Toyokawa, MD, PhD, Mitsuhiro.
Treatment of Lung Cancer with an ALK Inhibitor After EML4-ALK Fusion Gene Detection Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration 

Treatment of Lung Cancer with an ALK Inhibitor After EML4-ALK Fusion Gene Detection Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration 
Identification and Characterization of ALK Kinase Splicing Isoforms in Non–Small-Cell Lung Cancer  Lorena Lobo de Figueiredo-Pontes, MD, PhD, Daisy Wing-Sze.

Identification and Characterization of ALK Kinase Splicing Isoforms in Non–Small-Cell Lung Cancer  Lorena Lobo de Figueiredo-Pontes, MD, PhD, Daisy Wing-Sze.
Transbronchial Biopsy Needle Rinse Solution Used for Comprehensive Biomarker Testing in Patients with Lung Cancer  Yuichi Sakairi, MD, PhD, Kenichi Sato,

Transbronchial Biopsy Needle Rinse Solution Used for Comprehensive Biomarker Testing in Patients with Lung Cancer  Yuichi Sakairi, MD, PhD, Kenichi Sato,
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non–Small-Cell Lung Cancer Tumor Specimens Using Quantitative.

Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non–Small-Cell Lung Cancer Tumor Specimens Using Quantitative.
Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non– small-cell Lung Cancer Exhibiting Resistance to Ceritinib  Gouji Toyokawa,

Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non– small-cell Lung Cancer Exhibiting Resistance to Ceritinib  Gouji Toyokawa,
Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC- 2/ad  Daisuke Matsubara, MD, PhD, Yoshihiko Kanai, Shumpei Ishikawa,

Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC- 2/ad  Daisuke Matsubara, MD, PhD, Yoshihiko Kanai, Shumpei Ishikawa,
KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.

Similar presentations

Ads by Google